Is Afya Limited (AFYA) Undervalued? Valuation & Fair Price
At $13.60, 3 of the 4 frameworks would buy Afya Limited today — Warren Buffett, Benjamin Graham, and Peter Lynch rate it Buy and Phil Town (Rule #1) rates it Avoid. Each model calculates its own fair value and margin of safety; create a free account to see the exact buy price behind every verdict.
Afya Limited
AFYAConsumer Defensive · Education & Training Services · NASDAQ
$13.60
P/E 8.5×
CEO
Virgilio Deloy Capobianco Gibbon
Sector
Consumer Defensive
Industry
Education & Training Services
Website
institucional.afya.com.brAfya Limited, operating through its subsidiaries, is a prominent medical education provider in Brazil. The company delivers a comprehensive array of educational products and services primarily focused on the medical field, encompassing medical schools, preparatory courses for medical residency, advanced graduate studies, and various other programs tailored for medical professionals at all career stages. These offerings are available across its proprietary network and are also extended to external medical institutions. Beyond traditional education, Afya also offers digital health services through a subscription-based platform, accessible via a mobile app and website. This platform is specifically designed to assist healthcare practitioners and students with clinical decision-making by providing essential tools such as medical calculators, reference charts, up-to-date content, prescription guidance, clinical scoring systems, details on medical procedures, and laboratory examination information. While strong in medicine, Afya's educational portfolio spans a broader spectrum of health sciences, including dentistry, nursing, radiology, psychology, pharmacy, physical education, physiotherapy, nutrition, and biomedicine. Furthermore, the company extends its academic offerings beyond healthcare to include undergraduate and postgraduate degree programs in diverse subjects like business administration, accounting, law, civil engineering, industrial engineering, and pedagogy. The company further enhances its educational ecosystem by providing specialized postgraduate medical programs, both printed and digital educational materials, an online medical learning platform, and hands-on medical training opportunities. As of December 31, 2021, Afya maintained an extensive network of 46 undergraduate and graduate medical school campuses, which included 30 operational undergraduate units and five approved units. This infrastructure supported a total capacity of 2,731 medical school seats, with 2,481 actively operating and an additional 278 seats approved for future use. Established in 1999, Afya Limited is headquartered in Nova Lima, Brazil.
Investor scorecard
How the four investors rate Afya Limited
3 of 4 frameworks lean Buy
Investor model analysis
Details lockedAt $13.60, 3 of 4 frameworks say Buy
Intrinsic Value (DCF)
Warren Buffett's valuation model · select an investor above to switch
Intrinsic Value
Locked — upgrade to viewBuy Below
Locked — upgrade to viewStrong Buy
Locked — upgrade to viewMargin of Safety
Locked — upgrade to viewUnlock buy targets with a free account
Get startedCreate a free account to see buy targets, full checklists & risk analysis Get started
Insider & congress activity
Are insiders buying AFYA?
Over recent SEC Form 4 filings, AFYA insiders bought $0 and sold $3.2M of stock across 19 open-market trades. Insiders sell for many reasons, but they buy for one.
| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
| Junior Lelio De SouzaVice President | Sell | 36,204 | $543K | Jul 1, 2026 |
| Basolli Gomiero MirellaVice President | Sell | 10,000 | $148K | Jun 26, 2026 |
| Junior Lelio De SouzaVice President | Sell | 41,541 | $623K | Jun 26, 2026 |
| FERREIRA SANTOS WELDERController | Sell | 3,325 | $53K | Apr 17, 2026 |
| GRIFO DE SOUSA ANIBAL JOSEVP Legal, Comp., & Gov Rel. | Sell | 5,000 | $77K | Apr 13, 2026 |
Source: SEC Form 4 filings. Open-market buys & sells only. Not investment advice.
See the interactive insider chart & every tradeScenario analysis
Bear, base & bull
Three growth assumptions, three fair values — and where today's price lands
What's working
Key strengths
Identified by Buffett framework analysis
Company financials
5-Year Financials
Income statement highlights — annual, USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $705M | $643M | $559M | $453M | $334M |
| Rev. Growth | +9.7% | +14.9% | +23.5% | +35.5% | — |
| Net Income | $143M | $123M | $75M | $73M | $43M |
| Net Margin | 20.4% | 19.1% | 13.4% | 16.0% | 13.0% |
| EPS (Diluted) | $1.59 | $1.36 | $0.83 | $0.81 | $0.46 |
| Free Cash Flow | Locked — upgrade to view | Locked — upgrade to view | Locked — upgrade to view | Locked — upgrade to view | Locked — upgrade to view |
Full analysis included
See the complete picture for AFYA
Exact buy targets, margin of safety, detailed investor checklists, and risk breakdown — all frameworks, all numbers.
Free: 3 analyses/month · Pay per stock: $4.99 · Pro: $19.99/mo
More Consumer Defensive stocks
Educational Use Only · Not Financial Advice
Analysis, scores, valuations, and buy zones are derived from publicly documented investor frameworks (Buffett, Lynch, Benjamin Graham, Phil Town) for learning purposes only. They are not recommendations from licensed financial advisors. Past performance does not guarantee future results. Prices may be delayed up to 15 minutes. Always conduct your own research before making any investment decisions.